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Abstract Superoxide dismutase/catalase mimetics, such
as salen Mn complexes and certain metalloporphyrins,
catalytically neutralize reactive oxygen and nitrogen spe-
cies, which have been implicated in the pathogenesis of
many serious diseases. Both classes of mimetic are pro-
tective in animal models of oxidative stress. However, only
AEOL11207 and EUK-418, two uncharged Mn porphyrins,
have been shown to be orally bioavailable. In this study,
EUK-418 and several new analogs (the EUK-400 series)
were synthesized and shown to exhibit superoxide dismu-
tase, catalase, and peroxidase activities in vitro. Some also
protected PC12 cells against staurosporine-induced cell
death. All EUK-400 compounds were stable in simulated
gastric fluid, and most were substantially more lipophilic
than the salen Mn complexes EUK-189 and EUK-207,
which lack oral activity. Pharmacokinetics studies
demonstrate the presence of all EUK-400 series com-
pounds in the plasma of rats after oral administration.
These EUK-400 series compounds are potential oral ther-
apeutic agents for cellular damage caused by oxidative
stress.
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Introduction
An excess of reactive oxygen species (ROS) and reactive
nitrogen species (RNS) mediates cumulative damage to
tissues by oxidation of DNA and other macromolecules,
peroxidation of lipids, and nitration of tyrosine residues.
Mitochondrial injury, microvascular damage, and chronic
inflammatory events are also associated with the state of
oxidative stress. The brain is especially sensitive to oxidative
damage owing at least in part to its high rate of O2 con-
sumption and relative lack of antioxidant defenses [1–3].
Oxidative stress has been implicated in a number of neuro-
degenerative diseases, including Alzheimer’s disease, Par-
kinson’s disease, amyotrophic lateral sclerosis (ALS), and
Huntington’s disease, as well as atherosclerosis, chronic
inflammatory disease, rheumatoid arthritis, autoimmune
disease, and injury caused by exposure to ionizing radiation
[1, 3].
Superoxide dismutase (SOD)/catalase mimetics such as
salen Mn complexes and certain metalloporphyrins are
synthetic compounds that catalytically mimic both SOD
and catalase, neutralizing the ROS superoxide and hydro-
gen peroxide [4–6]. Some mimetics also neutralize, via
peroxidase-like mechanisms, RNS such as peroxynitrite
[7–9]. Treatment with salen Mn mimetics (such as EUK-
189) has been shown to protect against injury due to
oxidative stress in animal models of diseases, including
Parkinson’s disease [10], ALS [11], and Alzheimer’s dis-
ease [12], and stroke [13]. Treatment with EUK-189 or
EUK-207, a cyclized salen Mn complex, prevents age-
associated cognitive impairment in mice [14]. In addition,
treatment of mice lacking mitochondrial SOD (sod2-/-)
with EUK-189 is neuroprotective and increases median life
span from 8 to 30 days [15]. Recent evidence also dem-
onstrates that EUK-189 mitigates radiation damage in rat
lung [16] and prolongs survival of mice receiving a lethal
dose of total body radiation [17].
Metalloporphyrin SOD/catalase mimetics have also been
shown to protect against radiation injury [18–23] and CNS
disorders [24–27]. Many diseases characterized by oxidative
stress are chronic in nature. For such disorders an orally
active therapeutic agent would be highly desirable. The salen
Mn complexes (EUK-189 and EUK-207) lack oral bio-
availability and, like Mn porphyrins, are administered by
injection or infusion. Recently Liang et al. [27] described an
improved metalloporphyrin, 5,15-bis(methoxycarbonyl)-
10,20-bistrifluoromethylporphyrinato manganese(III) chlo-
ride (AEOL11207), found to be orally active and present in
the brains of treated mice. We and our collaborators have
also described two orally bioavailable low molecular weight
Mn porphyrins called ‘‘EUK-418’’ and ‘‘EUK-423’’ [28] that
are also found in the brain and other tissues of mice after oral
administration [29]. To our knowledge, no bioavailability
data are available for any other Mn porphyrins, including the
new lipophilic Mn porphyrin compounds described by
Lahaye et al. [30] and Trova et al. [31]. The goal of our study
was to develop several new EUK-400 series compounds and
characterize all EUK-400 compounds with respect to their
catalytic activities, oral bioavailability, and other relevant
properties.
Materials and methods
Materials
Tissue culture media, sera, and supplements were obtained
from Invitrogen (Carlsbad, CA, USA). BD BioCoat colla-
gen-coated plates were purchased from Becton, Dickinson
(Franklin Lakes, NJ, USA). Staurosporine (STS; catalog
no. 1 055 682) and 2,3-bis(2-methoxy-4-nitro-5-sulfophe-
nyl)-2H-tetrazolium-5-carboxanilide (XTT; catalog no. 1
465 015) were obtained from Roche (Indianapolis, IN,
USA). Acetonitrile was purchased from J.T. Baker (Phil-
lipsburg, NJ, USA). Formic acid and methanol were from
EMD Chemicals (obtained from VWR). Solvents for syn-
thesis were obtained in bulk from Fisher. The 4-tetrahydro-
pyran carboxaldehyde was purchased from Combi-Blocks
(San Diego, CA, USA). All other chemicals were obtained
from Sigma Chemicals (St Louis, MO, USA).
Animals
Sprague–Dawley rats were obtained from Charles River
Laboratories (Wilmington, MA, USA). Animal studies
giving the data in Table 3 were performed at TGA Sci-
ences (Medford, MA, USA). This facility is USDA-regis-
tered and AAALAC-accredited, and these studies were
supervised by an in-house Institutional Animal Care and
Use Committee. Animal studies giving the data in Fig. 3
were performed by Cerep (Redmond, WA, USA). Standard
operating procedures related to this work were reviewed
and approved by the Cerep Ethics Committee.
Inhibition of STS-induced cell death in PC12 cells
Rat pheochromocytoma (PC12) cells from adrenal gland
were purchased from the American Type Culture Collection
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(Rockville, MD, USA; catalog no. CRL 1721). Cells were
maintained in RPMI 1640 media with 12.5% equine serum
and 2.5% fetal bovine serum, 2 mM L-glutamine, and
100 U ml-1 penicillin/streptomycin at 37 C with 5% CO2.
For assay, cells were plated at a density of 10,000 cells ml-1
on collagen-coated 96-well microtiter plates. Lyophilized
STS was reconstituted in ethanol, and the concentration was
determined by UV absorption (e292 = 57.38 mM
-1 cm-1).
STS was added at various concentrations to induce cell
death. Test compounds were added together with the STS.
Cells were incubated overnight at 37 C, 5% CO2. After 18–
24 h, test medium was removed, and cell viability was
determined using the XTT viability assay [13].
Compound synthesis
The syntheses of EUK-418 and EUK-423 have been
described previously [29]. The synthesis of 5,15 porphyrins
(all the EUK-400 compounds except EUK-425) is shown in
Scheme 1. In a typical experiment, 2,20-dipyrromethane,
1 (100 mmol), prepared as described in [32], and the
appropriate aldehyde (100 mmol) were dissolved in 16 l
dichloromethane in a flask. Argon was bubbled into the
solution with stirring for 1 h. The contents were protected
from light and trifluoroacetic acid was added (22 mmol)
and the mixture was stirred 16 h. 2,3-Dichloro-5,6-di-
cyanobenzoquinone (150 mmol) was then added, and the
mixture was stirred for 1 h. Triethylamine was added
(10 ml) and the mixture was stirred 5 min. The porphyrin
was purified by column chromatography on silica with
elution with dichloromethane. These porphyrins were
characterized by 1H-NMR and thin-layer chromatography
(TLC).
Manganese incorporation is shown in Scheme 2 [33].
The 5,15 porphyrin (1 mmol) was dissolved in 100 ml
acetic acid. Manganese acetate tetrahydrate (6 mmol) and
sodium acetate (6 mmol) were added and the mixture was
heated at 100 C for 2 h. When the reaction was complete
as monitored by TLC, the heat was turned off and the red
solution cooled. Dichloromethane (500 ml) was added and
the organics were extracted with 5 9 250 ml H2O and then
1 9 50 ml brine. The organic layer was dried over sodium
sulfate. The compound was dissolved in dichloromethane
and slowly precipitated with hexane to give a copper-col-
ored crystalline solid that was washed with hexane and
dried under vacuum overnight. The ligand was presumed to
be acetate in the case of a neutral work-up or chloride when
the organic phase was washed with 1 N HCl. The purity
and identity of the subsequent Mn(III) 5,15-disubstituted
porphyrins was assessed by TLC, UV–vis spectroscopy,
electrospray ionization (ESI)–mass spectroscopy (MS), and
high-performance liquid chromatography (HPLC). For
TLC screening, compounds were applied to silica plates
which were run in 10% methanol, 20% ethyl acetate, and
70% dichloromethane. Samples were considered to be of
sufficient purity if there was a single spot of product and no
detection of starting materials. (More detailed chromatog-
raphy information, including retention times in HPLC
systems, is given below and in the electronic supplemen-
tary material, where chromatograms are shown.) UV–vis
spectra were obtained with a Beckmann DU7400 spectro-
photometer, using methanol as the solvent. HPLC methods
are described below. Elemental analysis, ESI-MS (includ-
ing methods used), HPLC chromatograms, and absorption
spectra of EUK-400 series compounds and multiple reac-
tion monitoring transitions monitored on liquid chroma-
tography with tandem MS (LC-MS/MS) are available
online as electronic supplementary material. The com-
pounds synthesized for this work, hereafter referred to by
their EUK designation, are summarized in Fig. 1a.
EUK-425, manganese(III) 5,10,15,20-tetraethylporphine
acetate, was prepared from 5,10,15,20-tetraethylporphyrin
[34] following the method of Meunier and Cosledan [29] as
shown in Scheme 3.
The 1H-NMR (CDCl3) data and yield obtained for each
unmetallated precursor compound are as follows: precursor
to EUK-418—5,15-dicyclopropylporphine, 10.13 (s, 2H),
9.92 (d, 4H), 9.35 (d, 4H), 4.21 (tt, 2H), 1.95 (dt, 4H),
1.75 (dt, 4H), -2.94 (bs, 2H), yield 56%; precursor to
N
NH N
HN
R
R
NH HN
1
R-CHO+
1. TFA
2. DDQ
CH2Cl2
Scheme 1 Synthesis of 5, 15 porphyrin ligands for all EUK-400
compounds except for EUK-425. TFA is trifluoroacetic acid and
DDQ is 2,3-dichloro-5,6-dicyanobenzoquinone. Further details are
described in Materials and methods
Scheme 2 Incorporation of metal to form Mn porphyrin complex for
all EUK-400 compounds except for EUK-425. Further details are
described in Materials and methods
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EUK-423—5,15-diphenylporphine, 11.88 (s, 2H), 9.40 (d,
4H), 9.09 (d, 4H), 8.28 (m, 4H), 7.82 (6H), -3.12
(bs, 2H), yield 63%; precursor to EUK-450—5,15-(3,4-
dimethoxyphenyl)porphine, 10.31 (s, 2H), 9.40 (d, 4H), 9.13
(d, 4H), 7.83 (m, 4H), 7.31 (d, 2H), 4.21 (s, 6H), 4.04 (s, 6H),
-3.11 (bs, 2H), yield 52%; precursor to EUK-451—5,15-
di(4-tetrahydropyranyo)porphine, 10.23 (s, 2H), 9.80 (bd,
4H), 9.44 (d, 4H), 5.48 (tt, 2H), 4.53 (dd, 4H), 4.12 (t, 4H),
1
1
22
EUK- L R1 R2
418 OAc cyclopropyl H 
423 OAc phenyl H 
425 OAc ethyl same as R1
    
450 OAc 3,4-methoxy-
phenyl
H
451 Cl 4-tetra-
hydropyrano
H
452 Cl cyclohexyl H 
453 Cl propyl H 
    
AEOL11207 Cl CO2CH3 CF3
MnTBAP Cl 4-benzoic acid same as R1
MnTMPyP Cl 1-methyl-4-
pyridyl
same as R1
A
B
Fig. 1 a Structures of EUK-
400 series compounds.
Structures are also given for the
related Mn porphyrins 5,15-
bis(methoxycarbonyl)-10,20-
bistrifluoromethylporphyrinato
manganese(III) chloride
(AEOL11207) [27],
manganese(III) tetrakis(4-
benzoic acid) porphyrin
(MnTBAP), and manganese(III)
tetrakis(1-methyl-4-pyridyl)
porphyrin (MnTMPyP) [5].
b Structures of the salen Mn
complexes EUK-189 and EUK-
207. OAc acetoxy (CH3COO)
H
N
+
O
H
N
NH N
HN N
N N
N
Mn OAc
Propionic acid
90-93oC
Mn(OAc)2 4H2O
CH2Cl2, MeOH, ∆
Scheme 3 Synthesis of EUK-
425, following the method of
Meunier and Cosledan [29]
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3.57 (dq, 4H), 2.63 (d, 4H), -2.49 (bs, 2H), yield 32%;
precursor to EUK-452—5,15-dicyclohexylporphine, 10.18
(s, 2H), 9.77 (bs, 4H), 9.40 (d, 4H), 5.22 (tt, 2H), 3.12 (dq,
4H), 2.76 (bd, 4H), 2.30 (dd, 6H), 1.98 (m, 6H), -2.45 (bs,
2H), yield 34%; precursor to EUK-453—5,15-dipropylpor-
phine, 10.17 (s, 2H), 9.58 (d, 4H), 9.41 (d, 4H), 5.00 (t, 4H),
2.57 (h, 4H), 1.33 (t, 6H), -2.93 (bs, 2H), yield 25%.
The ESI high-resolution MS (HRMS) and UV–vis data,
and the metallation yield obtained for each compound are as
follows: EUK-418, manganese(III) 5,15-dicyclopropylpor-
phine acetate, ESI-HRMS: anal. calc. for C26H20N4Mn
?
443.1068, observed 443.1059, UV–vis: kmax, nm; (e, M
-1
cm-1): 373 (40,814), 395 (37,382), 462 (58,498), yield 98%;
EUK-423: manganese(III) 5,15-diphenylporphine acetate,
ESI-HRMS: anal. calc. for C32H20N4Mn
? 515.1068,
observed 515.1071, UV–vis: 372 (66,532), 393 (49,164), 459
(72,914), yield 78%; EUK-425: manganese(III) 5, 10,15,
20-tetraethylporphine acetate, ESI-HRMS: anal. calc. for
C28H28N4Mn
? 475.1694, observed 475.1699. UV–vis: 380
(45,203), 402 (41,163), 471 (58,144), yield 36%; EUK-450:
manganese(III) 5,15-di-3,4-dimethoxyphenylporphine ace-
tate, ESI-HRMS: anal. calc. for C36H28N4O4Mn
? 635.1491,
observed 615.1503, UV–vis: 373 (45,564), 395 (43,122), 462
(68,535), yield 50%; EUK-451: manganese(III) 5,15-dite-
trahydropyranyoporphine chloride: ESI-HRMS: anal. calc.
for C30H28N4O2Mn
? 531.1593, observed 531.158, UV–vis:
372 (48,088), 393 (43,813), 460 (72,370), yield 95%;
EUK-452: manganese(III) 5,15-dicyclohexylporphine chlo-
ride, ESI-HRMS: anal. calc. for C32H32N4Mn
? 527.2007,
observed 527.1993, UV–vis: 374 (44,365), 394 (40,921),
461 (61,952), yield 97%; EUK-453: manganese(III) 5,15-d
ipropylporphine chloride, ESI-HRMS: anal. calc. for C26H24
N4Mn
? 447.1381, observed 447.1383, UV–vis: 374 (49,723),
395 (44,441), 462 (54,688), yield 95%.
Catalytic activity
Catalase activity was assayed by measuring the disap-
pearance of hydrogen peroxide in 96-well plates, measured
using horseradish peroxidase coupled oxidation of 2, 20-
azinobis(3-ethylbenzthiazoline-6-sulfonate) diammonium
salt (ABTS). The method was as described in [35], except
the initial hydrogen peroxide concentration was 100 lM,
and oxidation of ABTS was monitored at 690 nm to
eliminate interference from porphyrins. SOD activity was
measured indirectly in multiwell plates, using xanthine/
xanthine oxidase as the superoxide-generating system and
nitro blue tetrazolium (NBT) as the detector. Reduction of
NBT was monitored at 550 nm in a final volume of
0.21 ml. The temperature was maintained at 25 C. The
final concentrations of the reagents were as follows:
50 mM sodium phosphate, pH 7.8, 17.7 mU ml-1 xanthine
oxidase, 2,750 U ml-1 catalase, 250 lM xanthine, and
10 lM NBT. Another superoxide indicator, cytochrome c,
generated artifacts in this assay, consistent with the inter-
ference observed when using manganese(III) tetrakis
(4-benzoic acid) porphyrin (MnTBAP) analogs [31]. One
unit of activity was defined as the amount of compound
which blocked 50% NBT reduction under these conditions.
Bovine Cu/Zn SOD was used as a standard (Sigma
S-5395). Controls for the SOD assay include ensuring that
the compound does not affect the superoxide-generating
reaction, testing solvent alone, and ensuring that the com-
pound does not react independently with NBT. Peroxidase
activity was assessed in the presence of hydrogen peroxide
with tetramethyl benzidine as the substrate. The final
concentrations of the reagents were 5 lM sample, 0.2 mM
hydrogen peroxide, and 0.225 mM tetramethyl benzidine
in a volume of 1.1 ml at a temperature of 27 C. The
reaction was monitored at 655 nm. Controls for the cata-
lase and peroxidase assays include ensuring that the reac-
tions are hydrogen peroxide dependent.
Quantitation of compounds by HPLC
Samples from simulated gastric fluid (SGF) and octanol
partitioning studies were analyzed by HPLC using a Waters
model 2695 system equipped with a model 2996 photodiode
array detector. A Whatman Partisil 10 ODS-3 (4.6 mm
9 250 mm) column was used. The column was equilibrated
with 50% methanol and 50% 100 mM NaCl, and samples
were injected in a volume of 50 ll. All Mn porphyrins except
EUK-452 were eluted from the column at 1.0 ml min-1 with
a gradient to 80% methanol over 1 min. EUK-452 was eluted
with a gradient to 100% methanol over 1 min. A wavelength
of 458 nm was used for detection of all EUK-400 series
compounds. EUK-189 and EUK-207 compounds were
injected similarly onto a column equilibrated with 0%
methanol and 100% 100 mM NaCl, and were eluted with a
gradient to 60% methanol over 1 min. A wavelength of
324 nm was used for detection of salen Mn complexes.
Compound retention times in minutes were 12.9 (EUK-189),
12.8 (EUK-207), 10.9 (EUK-418), 11.9 (EUK-423),
11.5 (EUK-425), 11.2 (EUK-450), 10.0 (EUK-451), 10.8
(EUK-452), and 11.4 (EUK-453).
In vitro stability in SGF
To measure stability in USP SGF, compounds were diluted
in SGF (34 mM NaCl, 3.2 mg ml-1 pepsin, 81.2 mM HCl,
pH approximately 1.2) and incubated at 37 C for 90 min
(1 h is a standard gastric ‘‘transit time’’ according to the
FDA) [36]. Aliquots were withdrawn, and intact compound
was quantitated by HPLC–UV analysis as described
earlier.
J Biol Inorg Chem (2009) 14:979–991 983
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Lipophilicity measurements
Lipophilicity was determined by vortexing a mixture of
400 ll 500 lM compound and 200 ll octanol in a 1.7-ml
microfuge tube. The volumes and concentrations used
differed from those used in previous methods [15] to
optimize quantitation of the porphyrin compounds. Quan-
titation of the compound in each layer was performed by
HPLC–UV analysis. Octanol partitioning coefficients (P)
were expressed as the ratio of the concentration of the
sample in the octanol phase to that in the aqueous phase:
P ¼ ½EUKoct½EUK]aq
In vivo oral bioavailability
Aqueous solutions of compounds were administered to
Sprague–Dawley rats, and blood samples were collected
into vials pretreated with Li heparin at various time points
for extraction and measurement of the compound by LC-
MS/MS. Details are given in the figure legends.
Results
Synthesis and catalytic activities
Seven EUK-400 series compounds were synthesized
(Fig. 1a). Of these, EUK-418, EUK-423, and EUK-425
(originally compounds 3, 20, and 24, respectively) were
described in the original patent [29], and the others were
designed for this work. The design goals were to produce
Mn porphyrin compounds bisubstituted with pharmaco-
logically compatible substituents and having a range of
predicted lipophilicities between those of EUK-418 and
EUK-423. For comparison, the structures of the salen Mn
complexes EUK-189 and EUK-207 [14] are shown in
Fig. 1b. All EUK-400 series compounds exhibited signifi-
cant SOD activities (Table 1), although these activities
were lower than those of the salen Mn complexes.
Although the assay methods differed, the SOD activities of
the EUK-400 series compounds were comparable to that of
AEOL11207, when normalized to that of Cu/Zn SOD. (In
other words, the EUK-400 compounds are 26- to 205-fold
less active than Cu/Zn SOD, whereas AEOL11207 is 123-
fold less active [27].) In addition, all EUK-400 series
compounds had significant catalase and peroxidase activi-
ties (Table 1), although again at lower levels than those of
EUK-189 and EUK-207.
Recent work has shown that MnTBAP in fact possesses
no SOD activity [37]. Previously reported SOD activity
was due to Mn aggregate impurities in commercial
preparations. To rule out the possibility that similar
impurities in our preparations of EUK-400s are responsible
for catalytic activity, we analyzed samples by ESI-MS. No
peaks were observed at 341 or 381 (Fig. S1), which cor-
respond to these Mn aggregates [37]. Since Mn clusters are
sensitive to EDTA, whereas intact Mn porphyrins are not,
we incubated the diluted compounds with EDTA, and
found no change in activity. In addition, HPLC fractions of
EUK-451 exhibited SOD and catalase activities only in the
peak corresponding to intact compound (data not shown).
Protection against STS-induced cell death in PC12 cells
Previous studies have shown that salen Mn complexes
protect cultured cortical neurons from STS-induced apop-
tosis and concomitantly inhibit intracellular oxidative
stress [38]. In this study, we used the rat pheochromocy-
toma PC12 cell line, which is also sensitive to STS. Low
doses of EUK-418, EUK-423, and EUK-451 protect PC12
cells against STS-induced cell death (Fig. 2). EUK-425,
EUK-450, EUK-452, and EUK-453 were not significantly
protective and were cytotoxic (data not shown). The salen
Mn compounds EUK-189 and EUK-207 also show pro-
tection. Consistent with its greater stability [14], EUK-207
is more potent than EUK-189 in this model. Higher doses
of EUK-400 compounds (30–100 lM) are toxic in the
absence of STS, whereas EUK-189 and EUK-207 were not
toxic at any dose tested (data not shown). The biphasic
dose–response curve for the EUK-400 compounds in Fig. 2
is consistent with this observed toxicity.
Table 1 Catalytic activities of EUK-400 series compounds com-
pared with those of EUK-189 and EUK-207
Compound SOD IC50 (lM) CAT
(lM H2O2
min-1)
POD
(lM TMB
min-1)
EUK-189 0.37 3.15 ± 0.01 3.61 ± 0.05
EUK-207 0.48 3.21 ± 0.04 4.43 ± 0.003
EUK-418 1.73 0.47 ± 0.10 0.63 ± 0.08
EUK-423 6.36 0.45 ± 0.18 0.61 ± 0.05
EUK-425 12.5 0.57 ± 0.15 0.58 ± 0.03
EUK-450 6.39 0.58 ± 0.08 0.66 ± 0.10
EUK-451 3.36 0.64 ± 0.25 0.59 ± 0.023
EUK-452 11.6 0.54 ± 0.06 0.63 ± 0.05
EUK-453 5.95 0.50 ± 0.11 0.56 ± 0.03
Assays were performed as described in ‘‘Materials and methods.’’
EUK-400 series compounds were tested from dimethyl sulfoxide stock
solutions for superoxide dismutase (SOD) and catalase (CAT) activities,
and from H2O for peroxidase (POD) activity. EUK-189 and EUK-207
were diluted from a H2O stock solution. Standard deviations of tripli-
cate samples are given for CAT and POD. Under these conditions,
Cu/Zn SOD enzyme exhibited an IC50 value of 0.0011 lM
TMB tetramethyl benzidine
984 J Biol Inorg Chem (2009) 14:979–991
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In vitro ‘‘predictors’’ of oral availability
The purpose of these experiments was to conduct simple in
vitro tests that others have used as potential predictors of
oral availability. All EUK-400 series compounds are stable
to incubation in SGF at 37 C for 90 min (Table 2). This
time period is longer than the gastric transit time, sug-
gesting that degradation in the stomach is not a barrier to
oral availability. In contrast, EUK-189 was much less
stable, and EUK-207 had an intermediate stability that is
consistent with its survival in the gastrointestinal system
during the time period following oral ingestion. The EUK-
400 series compounds were originally designed for oral
availability [29]. As discussed above, EUK-450, EUK-451,
EUK-452, and EUK-453 were designed for this work as
lipophilic variations of EUK-418 and EUK-423. Thus,
octanol partitioning was performed as a measure of lipo-
philicity (Table 2). Besides its potential association with
oral absorption, this test may also have some predictive
value for the ability to cross membrane barriers such as the
blood–brain barrier. With the exception of EUK-451, all of
the EUK-400 series compounds are substantially more
lipophilic than EUK-189 or EUK-207, two salen Mn
complexes that have no oral bioavailability. EUK-452 was
the most lipophilic, with a log10 P value of 1.98; a value of
2 or greater may predict the ability to cross the blood–brain
barrier [39]. Another commonly used in vitro model for
oral availability is permeability through a Caco-2 mono-
layer [40–42]. We found that this model system was not
useful for the EUK-400 series compounds, because they
stuck to the cellular layer, so we proceeded to test the
compounds in vivo.
In vivo oral availability
One compound, EUK-425, was selected for a bioavail-
ability study comparing the pharmacokinetics of oral
versus intravenous routes of administration. When EUK-
425 was administered to rats by oral gavage and intra-
venous injection, the compound was detected in plasma
by LC-MS/MS (Fig. 3). Plasma levels dropped over the
first hour after intravenous administration, whereas they
remained relatively constant after administration by oral
gavage. Subsequently all EUK-400 series compounds
were administered to rats by oral gavage, and the plasma
was found to contain a sustained level of the compound
at time points up to 6 h (Table 3). Plasma levels of each
compound in each individual rat, averaged to produce
the data in Table 3, are shown in Table S2. Thus, all
compounds tested are orally available in rats. Our intent
was not to rank the compounds with respect to their oral
bioavailability, but to simply screen them in vivo to
demonstrate whether they could be delivered orally.
Consequently, each analog was administered at the most
Fig. 2 Some EUK-400 series compounds protect PC12 cells against
staurosporine (STS)-induced cell death. Rat pheochromocytoma
(PC12) cells were cultured in collagen-coated 96-well plates and
STS (5 lM) was added to induce cell death. Test compounds were
added together with the STS. After an 18–24-h incubation, test
medium was removed, and cell viability was determined using the
2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxa-
nilide viability assay, as described in ‘‘Materials and methods.’’
Control cells received no STS. In the absence of STS, the EUK-400
series compounds showed cytotoxicity at concentrations of 10–
30 lM. The data shown are direct comparisons of the compounds
using means of duplicates, and error bars indicate the range. These
data are representative of at least two additional independent tests of
each compound in triplicate
Table 2 Simulated gastric fluid (SGF) stability and octanol
partitioning
Compound SGF stability (%) P Log10 P
EUK-189 14 0.13 ± 0.00 -0.90 ± 0.013
EUK-207 72 0.04 ± 0.01 -1.41 ± 0.15
EUK-418 92 3.53 ± 0.14 0.548 ± 0.009
EUK-423 91 8.07 ± 0.10 0.907 ± 0.002
EUK-425 97 8.56 ± 0.35 0.932 ± 0.006
EUK-450 98 4.46 ± 0.11 0.650 ± 0.010
EUK-451 100 0.22 ± 0.01 -0.660 ± 0.011
EUK-452 98 94.0 ± 1.7 1.973 ± 0.008
EUK-453 98 4.16 ± 0.16 0.619 ± 0.017
EUK compounds were incubated with SGF for 90 min at 37 C.
Intact compound was quantitated by high-performance liquid chro-
matography (HPLC). Octanol partitioning was performed as descri-
bed in ‘‘Materials and methods,’’ except for EUK-207, for which the
volumes and concentrations were as described in [15]. The compound
in octanol and aqueous phases was quantitated by HPLC, and stan-
dard deviations of triplicate samples are given
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convenient dose on the basis of factors such as solubil-
ity. Under similar conditions, with oral doses as high as
50 mg kg-1, EUK-189 and EUK-207 are undetectable in
plasma (data not shown).
Discussion
Overall, the EUK-400 compounds exhibit biological
properties consistent with their potential value as thera-
peutic agents, including scavenging of ROS and cytopro-
tective activities. In this respect, these low molecular
weight Mn porphyrins share some similarities to the salen
Mn complexes but, in addition, they show oral bioavail-
ability, as hypothesized. To facilitate discussion of com-
parisons among the compounds, Table 4 summarizes their
relative properties.
EUK-400s are SOD/catalase mimetics with peroxidase
activity
As many metalloporphyrins have been demonstrated to
neutralize ROS, we tested the EUK-400 series compounds
for antioxidant activity. Relative to the salen Mn com-
plexes [4], the EUK-400 series compounds have lower
SOD, catalase, and peroxidase activities (Table 1). Among
the EUK-400 series, the compounds have similar catalase
and peroxidase activities; however, their SOD activities
vary about tenfold from the most active (EUK-418) to the
least active (EUK-425). These results contrast with the
structure–activity relationship we have reported for a series
of salen Mn complexes, which have similar SOD activities,
but varying catalase and peroxidase activities [4]. Because
of the lack of any obvious trends and the limited number of
EUK-400 series compounds examined, no strong structure–
activity relationships can be established, but that was not
the intent of this study. Nonetheless, we speculate that
differences in SOD activity may in part be related to steric
differences among the compounds. For example, EUK-418
with its two cyclopropyl groups has an almost fivefold
greater SOD activity than EUK-453 with its two linear
propyl chains, and might be expected to have a less planar
(more ‘‘ruffled’’) structure owing to the bulkier cyclopropyl
groups at two of its meso positions [43]. This in turn should
affect the coordination of Mn in relation to the porphyrin,
potentially favoring SOD catalytic activity [37, 44]. For the
compounds with cycloalkyl groups at the meso positions,
the SOD activity seems to be inversely related to the steric
bulk of these substituents. The 1H-NMR spectra of the
unmetallated precursors to these compounds confirm that
the relative steric interactions are EUK-452 [ EUK-
451 [ EUK-418 (less planar to most planar/free spinning).
The b protons closest to the cycloalkyl groups are broad-
ened in the 5,15-dicyclohexyl porphyrin, less broadened in
the 5,15-ditetrahydropyranoporphryin, and not broadened
at all in 5,15-dicyclopropyl porphyrin. Other factors such
as electronics and lipophilicity may also affect SOD
activity, and studying a broader series of compounds
might provide evidence to address such speculations. For
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Fig. 3 In vivo oral availability of EUK-425 in rats. EUK-425 was
administered to Sprague–Dawley rats (n = 3) by intragastric gavage
(PO) or intravenous injection (IV). The compound was formulated in
dimethyl sulfoxide/Solutol HS 15/phosphate-buffered saline, pH 7.4
(5:5:90, by volume), and the doses were 5 mg kg-1 for PO and
1 mg kg-1 for IV administration. The final volumes administered
were 1.35–1.53 ml. Plasma was collected from a jugular vein catheter
at various time points, and quantitation of compounds was performed
by liquid chromatography with tandem mass spectroscopy. Fifty
microliters of plasma was precipitated with 200 ll acetonitrile, and
the supernatant was analyzed using a TSQ Quantum machine. Ten-
microliter aliquots were injected for analysis. The high performance
liquid chromatography column was Synergi Fusion-RP 80, 4 lm
(2 mm 9 50 mm). The runs were performed at a flow rate of
0.5 ml min-1 with mobile phase A consisting of 13.3 mM
ammonium formate, 6.7 mM formic acid in water. Mobile phase B
was 6 mM ammonium formate, 3 mM formic acid in water/acetoni-
trile (1:9 v/v). The gradient was 20–100% mobile phase B over
2.5 min. The apparent molecular ion for EUK-425 was 516.0
m/z ? 475.2 m/z
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example, with a larger group of compounds one could vary
separately the solubility, electronics, and steric bulk at the
meso position of the porphyrin to see if any logical trends
based on these factors develop.
It is interesting to note that, in contrast to many bio-
logically active Mn porphyrins previously reported in the
literature, all the EUK-400 series compounds except EUK-
425 have two unsubstituted meso positions. In fact, Trova
et al. [31] reported that many Mn porphyrins having two
unsubstituted meso positions have greater catalase activity
and greater inhibition of lipid peroxidation than other
MnTBAP analogs.
Some EUK-400s protect PC12 cells against cell death
induced by STS
There was no close correlation between SOD or catalase
activity of these compounds and their ability to protect PC12
cells against apoptosis. We would not have expected a close
association because of the complexity of the cellular model
as compared with the individual catalytic activity assays.
Similarly, the ROS scavenging properties of a series of salen
Mn complexes did not directly predict their relative activities
in cell culture or in vivo [4]. In the current circumstance, all
Table 3 In vivo oral availability of EUK-400 series compounds in rats
Compound Dose (mg kg-1) Plasma concentration (ng ml-1)
30 min 60 min 120 min 240 min 360 min
EUK-418 0.96 128 ± 83 250 ± 147 245 ± 145 299 ± 224 259 ± 166
EUK-423 0.52 25 ± 7 53 ± 19 48 ± 23 110 ± 61 118 ± 17
EUK-425 1.7 52 ± 19 48 ± 21 78 ± 47 96 ± 20 113 ± 15
EUK-450 2.7 11 ± 10 15 ± 9 48 ± 46 53 ± 53 47 ± 38
EUK-451 0.93 44 ± 38 61 ± 54 66 ± 62 107 ± 102 86 ± 70
EUK-452 1.6 57 ± 50 52 ± 42 75 ± 63 75 ± 76 71 ± 63
EUK-453 0.23 8.8 ± 5.9 8.1 ± 5.5 7.7 ± 6.1 7.7 ± 6.0 4.6 ± 4.2
EUK-400 compounds (formulated in 0.3 g ml-1 sodium cholate in a final volume of 1.0–1.5 ml) were administered by intragastric gavage to
Sprague–Dawley rats in quadruplicate (n = 3 for EUK-450). Plasma was collected by orbital bleeding at various time points, and quantitation of
compounds was performed by liquid chromatography with tandem mass spectroscopy (LC-MS/MS). Vials were centrifuged to separate the
plasma. Plasma was transferred to fresh vials and chilled in ice before freezing it at -80 C. Extraction and protein precipitation were done in the
same step by adding 40 ll of thawed plasma sample to 1.5 ml of LC-MS/MS mobile phase (3 mM ammonium acetate, 0.065% formic acid,
33.2% acetonitrile, 33.2% methanol) and mixing well. After centrifugation, 50 ll of the supernatant was injected for analysis. A Waters model
2690 HPLC system was used with a Whatman Partisil 10 ODS-3 column (4.6 mm 9 100 mm), followed by a Quattro LC instrument manu-
factured by Micromass. The runs were performed isocratically at a flow rate of 0.5 ml min-1 with a mobile phase of 3 mM ammonium acetate,
0.065% formic acid, 33.2% acetonitrile, and 33.2% methanol. EUK-425 and EUK-452 required a mobile phase of 3 mM ammonium acetate,
0.065% formic acid, 36% acetonitrile, and 36% methanol. Four multiple reaction monitoring transitions were monitored for each compound (see
the electronic supplementary material). The following transitions were used for quantitation: for EUK-418, 484.11 m/z ? 442.80 m/z; for EUK-
423, 556.20 m/z ? 514.93 m/z; for EUK-425, 475.21 m/z ? 430.02 m/z; for EUK-450, 634.95 m/z ? 618.77 m/z; for EUK-451, 571.95 m/
z ? 530.84 m/z; for EUK-452, 527.05 m/z ? 399.77 m/z; for EUK-453, 488.07 m/z ? 446.94 m/z. Standard curves for this study had the most
useful quantitation range of 4.5–7,600 ng ml-1, although the limits of detection were even lower for many of the compounds. Under similar
conditions, EUK-189 and EUK-207, which can be quantitated with similar sensitivity, are undetectable in plasma after oral administration of up
to 50 mg kg-1, although they are readily detectable when given by injection (data not shown)
Table 4 Summary of properties of EUK compounds
Compound SOD CAT POD PC12 TOX LIP SGF ORAL
EUK-189 1 ?? ?? ? - 8 - -
EUK-207 1 ?? ?? ?? - 9 ? -
EUK-418 2 ? ? ? ?? 6 ?? ?
EUK-423 4 ? ? ??? ? 3 ?? ?
EUK-425 5 ? ? - ?? 2 ??? ?
EUK-450 4 ? ? - ?? 4 ??? ?
EUK-451 3 ? ? ??? ? 7 ??? ?
EUK-452 5 ? ? - ?? 1 ??? ?
EUK-453 4 ? ? - ?? 5 ??? ?
Data described elsewhere in the paper are summarized here to facil-
itate comparison among compounds. For lipophilicity (LIP), com-
pounds are ranked with respect to their octanol partitioning
coefficients (Table 2), with 1 being most lipophilic. For SOD activity
(Table 1), compounds are assigned scores from 1 (highest activity) to
5 (lowest activity). For the other parameters, ? and - scores are used
to enable semiquantitative comparisons among compounds. CAT and
POD are CAT and POD activities (Table 1), respectively. PC12
represents cytoprotective activity at lower, less toxic doses (less than
4 lM; Fig. 2), so is an indicator of relative potency. TOX represents
cytotoxic activity in PC12 cells (Fig. 2), as well as capillary endo-
thelial cells [23], at higher doses (more than 10 lM). SGF is the
stability in SGF (Table 2), and ORAL represents whether or not the
compound, administered orally at up to 50 mg kg-1, is orally avail-
able in rats (Fig. 3, Table 3)
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the EUK-400 compounds are cytotoxic at certain doses, and
this property most certainly influences their relative activi-
ties in an assay for cytoprotection. In the PC12 assay, EUK-
423 and EUK-451 were the most protective of the seven Mn
porphyrins tested, although both showed biphasic dose
curves consistent with their cytotoxicity. Although they both
had relatively high SOD activities, this property alone was
not sufficient. EUK-418, the compound with the highest
SOD activity, was a relatively poor protector in the PC12
model, most likely owing to its greater toxicity (Table 4).
Similarly, in an endothelial cell culture model, we showed
that EUK-418 and EUK-423, as well as EUK-189 and EUK-
207, mitigated apoptosis induced by ionizing radiation, with
EUK-418 showing the greatest cytotoxicity of the four,
EUK-423 showing intermediate toxicity, and the salen Mn
complexes showing no detectable toxicity [23]. We subse-
quently demonstrated that EUK-451 was also a potent mit-
igator in this model, and had significantly lower cytotoxicity
than the other EUK-400 compounds (unpublished data).
Four compounds, EUK-450, EUK-452, EUK-453, and
EUK-425, were the most cytotoxic and, not surprisingly,
showed no cytoprotective activity against STS-induced
apoptosis. Overall, the cytotoxicity of the EUK-400 series
compounds strongly influences observed cytoprotection.
Highly protective, less toxic compounds are favored in this
or in any other cellular model. Such differences will not be
evident, of course, in an SOD or catalase activity assay. For
this and other reasons, direct associations between such
specific ROS scavenging activities and cytoprotective
activity would not be predicted. Furthermore, no cellular
model will absolutely predict relative activity and toxicity in
vivo [4]. In addition, mechanisms other than ROS scaveng-
ing activity may also contribute to the cytoprotective activity
of the EUK-400 series compounds in a given model (see
below). Previous work with salen Mn complexes has shown
that other properties, such as intracellular accessibility and
stability, are at least as important as catalytic activity in
predicting cytoprotective activity [4, 38]. Consistent with
these findings, EUK-207 is more protective than EUK-189 in
the PC12 assay (Fig. 2), although these compounds have
similar catalytic activities (Table 1). Although cytotoxicity
is not an issue with these two analogs at the concentrations
tested, we previously showed that a salen Mn complex with
very high catalase activity, EUK-178, showed cytotoxicity in
cell culture as well as poor activity in vivo [4].
It is extremely interesting that, despite their lower SOD
and other ROS scavenging activities, EUK-451 and EUK-
423 protected PC12 cells at lower concentrations than did
the salen Mn complexes. This greater apparent potency
may very well be related to enhanced intracellular stability
since the Mn porphyrins are inherently more stable than the
salen Mn complexes as evidenced, for example, in the SGF
stability studies. In addition, it is quite possible that Mn
porphyrins have more complex mechanisms of cytopro-
tection than salen Mn complexes (see the discussion later).
In general, it is clear from these and our previous find-
ings that in vitro ROS scavenging activity is unlikely to
directly predict activity in cellular models. Consistent with
this, others have shown that the in vitro catalytic activities
of various ROS scavengers do not correlate with survival
of retinal ganglion cells [45]. Again, this finding is not at
all surprising given the potential complexity of any cyto-
protection assay. Similar to our observations in the ionizing
radiation studies cited above, Fig. 2 shows that the salen
Mn complexes do not display the dose-limiting cytotoxic-
ity seen in vitro with the EUK-400 series compounds.
Although it is promising that no toxicity was observed in
the in vivo oral availability studies reported here (Fig. 3,
Table 3), no formal toxicity studies have yet been done
with the EUK-400 compounds. Further studies using var-
ious relevant in vivo models will eventually help to predict
the best candidate(s) for potential therapeutic use. Indeed,
bioavailability properties will play a key role in this
selection.
SGF and octanol partitioning are useful, but insufficient
predictors of oral bioavailability
We performed these tests because others have found them
helpful in predicting oral availability. Unfortunately,
transport across Caco-2 cell monolayers was an unsuitable
model system for these compounds owing to their sticking
to the cell layer. Not surprisingly, octanol partitioning data
alone do not correlate with oral bioavailability. EUK-189
and EUK-451 have similar P values (Table 2); however,
EUK-451 is orally bioavailable, whereas EUK-189 is not.
The EUK-400 series compounds exhibited a wide range of
partitioning coefficients, and all exhibited oral availability.
It is possible that a common mechanism operates to
transport these porphyrins into the bloodstream; an intes-
tinal heme transporter has been identified [46]. Once in the
bloodstream, EUK-400s may bind to serum albumin, as do
other porphyrins [47], and as we have observed in vitro
with EUK-418, EUK-423, and EUK-425 (data not shown).
Stability in SGF is necessary, but not sufficient to predict
oral availability. For example, EUK-207 has sufficient
stability in SGF on the basis of gastric transit time, yet it is
not orally bioavailable. On the basis of its structure, one
would not expect EUK-207 to be recognized by a heme
transporter.
In vivo oral availability in rats
Previous work [29] showed that EUK-418 is orally bio-
available in mice, and this compound was detected in
selected tissues (kidney [ liver [ lung  brain). The
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present work compares the plasma levels of one compound,
EUK-425, when administered orally and intravenously
(Fig. 3) and also demonstrates the oral availability of all
EUK-400 series compounds (Table 3). As yet, the tissue
distribution of orally administered EUK-400 compounds in
rats is unknown. Given that ROS are implicated in neuro-
degeneration, it is of great interest to learn if any of
these compounds pass through the blood–brain barrier.
AEOL11207, another lipophilic metalloporphyrin, was
shown to be present in the brain tissue of mice after sub-
cutaneous or oral administration [27]. It is possible that
different analogs will be appropriate for different target
tissues. Our future in vivo studies will include investigation
of this question.
Speculation on mechanism of action
The conventional thinking is that SOD/catalase mimetics
protect against oxidative stress by neutralizing ROS in
vivo, and EUK-400 series compounds may also act by this
mechanism. According to a recent paper by Abramov et al.
[48], neurons exposed to anoxia and reperfusion exhibit at
least three different mechanisms of ROS generation: an
initial mitochondrial burst, a delayed xanthine oxidase
mediated production, and an NADPH oxidase dependent
production upon reoxygenation. Thus, different SOD mi-
metics may have different site(s) of action, depending on
their subcellular localization. Since the EUK compounds
exhibit a wide range of partition coefficients (Table 2),
they might be expected to migrate into different subcellular
compartments. Schlieve et al. [45] recently found a lack of
correlation between the activities of ROS scavengers,
including manganese(III) tetrakis(1-methyl-4-pyridyl)
porphyrin (MnTMPyP), in cell-free catalytic assays and in
cultured retinal ganglion cells, consistent with other find-
ings that catalytic activity in vitro does not correlate to
cytoprotection in vivo.
As noted above, the EUK-400 series compounds protect
cells at lower concentrations than the salen Mn complexes
EUK-189 and EUK-207, even though their catalytic
activities are lower. Besides their potential for greater
intracellular stability (see Table 2), it is also possible that
EUK-400 series compounds act via an additional or alter-
native mechanism which does not involve ROS. Other
groups have proposed alternative mechanisms of action for
Mn porphyrins. MnTBAP inhibits nuclear translocation of
apoptosis-inducing factor [49] and N-methyl D-aspartate
receptor mediated increases in intracellular Ca2? levels
[50]. Iron tetrakis(4-benzoic acid) porphyrin and cobalt
tetrakis(4-benzoic acid) porphyrin increase expression of
heme oxygenase-1 [51], an effect which correlates with the
protection of cardiomyocytes against apoptosis by doxo-
rubicin [52]. MnTMPyP scavenges NO and inhibits soluble
guanylyl cyclase activity [53]. It also inhibits the activity of
purified NO synthase by interfering with its reductase
domain [53]. Another possible antiapoptotic mechanism
which we have recently considered is inhibition of the
mitochondrial permeability transition. Protoporphyrin IX
binds to the peripheral benzodiazepam receptor (PBR) [54]
and participates in the induction of the mitochondrial
permeability transition [55]. Other PBR ligands inhibit
apoptosis [56, 57]. Preliminary data show that some of
these compounds have affinity for the PBR [58], although
the physiological implications are as yet unknown. The
complexity of the mechanisms by which these and similar
compounds exert their cytoprotective properties is an
avenue for much future research.
Therapeutic potential
Other Mn porphyrins have been proposed as possible
therapeutics for various medical conditions. As described
in ‘‘Introduction,’’ Mn porphyrins and salen Mn provide
neuroprotection in many disease models in vivo. Clinical
trials are now under way for manganese(III) tetrakis(N,N0-
diethylimidazolium-2-yl) porphyrin (AEOL10150), an
injectable Mn porphyrin, for treatment of ALS [59]. In
addition to their therapeutic potential in diseases of the
CNS, SOD/catalase mimetics should be effective in treat-
ing peripheral diseases such as diabetes [60] and heart
disease [61]. Recent studies have also suggested a role for
salen Mn complexes and Mn porphyrins as medical
countermeasures against radiation injury [16, 17, 18, 19,
22, 23]. Oral bioavailability is a useful property for a subset
of these therapeutic indications, whereas an injectable or
sustained-release formulation will be appropriate for
others.
In summary, we analyzed EUK-418 and several new
analogs. These compounds, called the ‘‘EUK-400 series,’’
are SOD and catalase mimetics, some of which protect
cultured cells from STS-induced cell death. Unlike the
salen Mn complexes such as EUK-189 and EUK-207, the
EUK-400 series compounds are detected in plasma after
oral administration. Thus, they are potential orally
administered therapeutics for diseases in which oxidative
stress is involved as well as injuries caused by radiation
exposure.
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